| 汪静,周海斌,顾伟刚,王霞,杨建锋.匹维溴铵联合胆舒胶囊治疗慢性胆囊炎的疗效与安全性[J].浙江中西医结合杂志,2019,29(6): |
| 匹维溴铵联合胆舒胶囊治疗慢性胆囊炎的疗效与安全性 |
| Clinical efficacy and safety of the treatment on chronic cholecystitis with pinaverium bromide combined with Danshu capsuleJing Wang 1, Hai-bin Zhou 2, Wei-gang Gu 3, Xia Wang 3, Jian-feng Yang 3,#. |
| 投稿时间：2018-11-28 修订日期：2019-04-22 |
| DOI： |
| 中文关键词: 匹维溴铵 胆舒胶囊 慢性胆囊炎 临床疗效 安全性 |
| 英文关键词:pinaverium bromide Danshu capsule chronic cholecystitis clinical efficacy safety |
| 基金项目: |
|
| 摘要点击次数: 789 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的：评价匹维溴铵联合胆舒胶囊治疗慢性胆囊炎的临床疗效与安全性。方法：将2014.1---2016.12月在我院消化内科就诊的慢性胆囊炎患者随机分为治疗组和对照组,治疗组予匹维溴铵50mg,tid,胆舒胶囊0.45g*2粒,tid,口服；对照组予胆宁片 5片,tid,口服,疗程均为4周。对比两组患者治疗前后腹部症状总评分、胆囊炎症改善和药物不良反应发生情况。结果：1. 共纳入患者379例,治疗组194例,对照组185例,两组间在性别、年龄、合并胆囊结石比例、体质指数、肝功能等差异无统计学意义。2. 治疗4周后治疗组患者腹部症状总评分明显低于对照组(2.1±0.3 比6.7±0.65,P=0.02)；治疗组症状缓解总有效率明显高于对照组(73.7% vs.42.2%),差异有统计学意义(P<0.001)3. 治疗后治疗组胆囊壁厚度(2.1±0.5比4.8±0.9,P=0.04)明显低于对照组；治疗组胆囊炎症改善总有效率明显高于对照组(68.6% 比 41.1%,P<0.001),差异有统计学意义；4.治疗组药物不良反应发生率明显低于对照组[3.1%(6/194)比12.2%(23/185),P=0.001]。结论：匹维溴铵联合胆舒胶囊能明显缓解慢性胆囊炎腹部症状,改善胆囊炎症,且不良反应少,是一种安全有效的药物治疗方法。 |
| 英文摘要: |
| Aim: To evaluate Clinical efficacy and safety of the treatment on chronic cholecystitis with pinaverium bromide combined with Danshu capsule. Methods: Patients with chronic cholecystitis were randomly divided into two group: treatment group and control group in January 2014—December 2016. Patients in treatment group were treated with pinaverium bromide combined with Danshu capsule, and patients in control group were treated with Danning capsule. Total symptoms score and adverse event were followed-up and record, gallbladder inflammation were measured by B-ultrasound examination. Results: 379 patients with chronic cholecystitis were included, 194 patients in treatment group and 185 in control group; gender, age, proportion of combined gallstones, body mass index, liver function between the two groups were no statistically significant differences; 2.After treatment, the total symptoms score in treatment group were significantly lower than these in control group(2.1±0.3 vs. 6.7±0.65,P=0.02), total effective rate in treatment group was significantly higher than control group(73.7% vs. 42.2%, P<0.001); 3. After treatment, the gallbladder wall thickness (2.1±0.5 vs.4.8±0.9, P=0.04)in treatment group were significantly lower than control group ; 4. The incidence of adverse events in treatment group was obviously lower than control group (3.1% (6/194) vs.12.2% (23/185), P=0.001). Conclusion: pinaverium bromide combined with Danshu capsule is an effective and safe treatment for chronic cholecystitis, for which could significantly relieve abdominal symptoms, improve gallbladder inflammation, and less adverse events. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
